See more : Striker Oil & Gas, Inc. (SOIS) Income Statement Analysis – Financial Results
Complete financial analysis of Nu Skin Enterprises, Inc. (NUS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nu Skin Enterprises, Inc., a leading company in the Household & Personal Products industry within the Consumer Defensive sector.
You may be interested
- East China Engineering Science and Technology Co., Ltd. (002140.SZ) Income Statement Analysis – Financial Results
- Nevaro Capital Corporation (NVPLF) Income Statement Analysis – Financial Results
- CH Biotech R&D Co., Ltd. (6534.TW) Income Statement Analysis – Financial Results
- AGP Corporation (9377.T) Income Statement Analysis – Financial Results
- Ahluwalia Contracts (India) Limited (AHLUCONT.NS) Income Statement Analysis – Financial Results
Nu Skin Enterprises, Inc. (NUS)
About Nu Skin Enterprises, Inc.
Nu Skin Enterprises, Inc. develops and distributes beauty and wellness products worldwide. It provides skin care systems, including ageLOC Spa systems, ageLOC Transformation anti-aging skin care systems, and ageLOC LumiSpa skin treatment and cleansing devices; and ageLOC Boost, as well as a range of other cosmetic and personal care products. The company also offers ageLOC Youth nutritional supplements, ageLOC TR90 weight management and body shaping systems, LifePak nutritional supplements, ageLOC Meta nutritional supplements, and Beauty Focus Collagen+ skin care supplements, as well as other weight management products. In addition, it is involved in the research and product development of skin care products and nutritional supplements. Further, the company operates retail stores and service centers in Mainland China. It sells its products under the Nu Skin, Pharmanex, and ageLOC brands. The company promotes and sells its products directly, as well as through distributors and Website. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.97B | 2.23B | 2.70B | 2.58B | 2.42B | 2.68B | 2.28B | 2.21B | 2.25B | 2.57B | 3.18B | 2.17B | 1.74B | 1.54B | 1.33B | 1.25B | 1.16B | 1.12B | 1.18B | 1.14B | 986.46M | 964.07M | 885.62M | 879.76M | 894.20M | 913.50M | 890.50M | 678.60M | 358.60M |
| Cost of Revenue | 611.85M | 630.92M | 675.22M | 658.03M | 581.42M | 634.14M | 502.08M | 500.46M | 489.51M | 478.43M | 505.81M | 353.15M | 322.62M | 272.43M | 243.65M | 228.60M | 209.28M | 195.20M | 206.16M | 191.21M | 176.55M | 190.87M | 178.08M | 111.74M | 118.50M | 169.10M | 224.40M | 187.80M | 94.60M |
| Gross Profit | 1.36B | 1.59B | 2.02B | 1.92B | 1.84B | 2.04B | 1.78B | 1.71B | 1.76B | 2.09B | 2.67B | 1.82B | 1.42B | 1.26B | 1.09B | 1.02B | 948.38M | 920.21M | 974.77M | 946.65M | 809.91M | 773.20M | 707.54M | 768.02M | 775.70M | 744.40M | 666.10M | 490.80M | 264.00M |
| Gross Profit Ratio | 68.93% | 71.65% | 74.95% | 74.51% | 75.98% | 76.33% | 77.97% | 77.33% | 78.22% | 81.38% | 84.08% | 83.72% | 81.50% | 82.28% | 81.70% | 81.68% | 81.92% | 82.50% | 82.54% | 83.20% | 82.10% | 80.20% | 79.89% | 87.30% | 86.75% | 81.49% | 74.80% | 72.33% | 73.62% |
| Research & Development | 22.60M | 23.30M | 27.20M | 23.30M | 30.10M | 23.00M | 22.00M | 24.30M | 20.10M | 18.90M | 18.00M | 14.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 546.86M | 555.77M | 666.40M | 646.85M | 615.97M | 662.30M | 564.51M | 554.15M | 561.46M | 622.30M | 640.03M | 505.45M | 436.18M | 401.42M | 378.34M | 364.25M | 361.24M | 353.41M | 354.22M | 333.26M | 289.93M | 0.00 | 636.06M | 640.00M | 612.80M | 533.60M | 503.60M | 0.00 | 0.00 |
| Selling & Marketing | 742.37M | 879.63M | 1.07B | 1.02B | 955.60M | 1.07B | 938.02M | 922.08M | 951.37M | 1.12B | 1.48B | 970.22M | 751.45M | 646.35M | 550.64M | 529.37M | 496.45M | 480.14M | 497.42M | 487.63M | 407.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.29B | 1.44B | 1.73B | 1.67B | 1.57B | 1.73B | 1.50B | 1.48B | 1.51B | 1.74B | 2.12B | 1.48B | 1.19B | 1.05B | 928.97M | 893.62M | 857.70M | 833.55M | 851.64M | 820.89M | 697.01M | 667.39M | 636.06M | 640.00M | 612.80M | 533.60M | 503.60M | 357.10M | 203.20M |
| Other Expenses | -21.69M | -21.88M | -1.53M | -1.33M | -12.25M | -21.19M | -8.92M | -18.27M | -32.74M | -53.68M | 2.83M | 4.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20.84M | 0.00 | 0.00 | 0.00 | 191.29M | 169.37M | 37.60M | 33.20M | 41.00M | 24.00M | 5.40M | 2.00M |
| Operating Expenses | 1.29B | 1.44B | 1.73B | 1.67B | 1.57B | 1.73B | 1.50B | 1.48B | 1.51B | 1.74B | 2.12B | 1.48B | 1.19B | 1.05B | 928.97M | 893.62M | 857.70M | 854.39M | 851.64M | 820.89M | 697.01M | 667.39M | 636.06M | 677.61M | 646.00M | 574.60M | 527.60M | 362.50M | 205.20M |
| Cost & Expenses | 1.90B | 2.07B | 2.41B | 2.32B | 2.15B | 2.37B | 2.00B | 1.98B | 2.00B | 2.22B | 2.62B | 1.83B | 1.51B | 1.32B | 1.17B | 1.12B | 1.07B | 1.05B | 1.06B | 1.01B | 873.56M | 858.26M | 814.14M | 789.35M | 764.50M | 743.70M | 752.00M | 550.30M | 299.80M |
| Interest Income | 0.00 | 10.38M | 11.16M | 13.12M | 19.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 21.88M | 11.00M | 13.10M | 19.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.80M | 6.90M | 7.80M | 7.80M | 8.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 69.60M | 72.51M | 125.02M | 120.15M | 121.11M | 83.00M | 71.56M | 72.40M | 71.37M | 54.92M | 34.92M | 33.41M | 32.85M | 29.62M | 28.56M | 30.39M | 32.97M | 29.13M | 31.37M | 28.66M | 23.08M | 21.60M | 32.43M | 37.60M | 33.20M | 41.00M | 24.00M | 5.40M | 2.00M |
| EBITDA | 137.66M | 231.85M | 368.48M | 331.56M | 267.43M | 394.55M | 346.05M | 303.50M | 316.07M | 407.11M | 589.04M | 374.26M | 266.59M | 246.68M | 176.58M | 138.85M | 109.75M | 86.91M | 154.91M | 125.76M | 135.98M | 105.81M | 71.48M | 128.02M | 162.90M | 210.80M | 212.20M | 149.20M | 60.80M |
| EBITDA Ratio | 6.99% | 9.34% | 12.53% | 12.84% | 11.05% | 14.27% | 12.04% | 10.47% | 10.89% | 13.71% | 17.44% | 15.71% | 13.80% | 14.73% | 13.20% | 12.04% | 12.60% | 11.56% | 13.44% | 13.89% | 14.31% | 13.52% | 10.79% | 13.87% | 18.37% | 23.08% | 17.05% | 19.29% | 16.82% |
| Operating Income | 48.27M | 110.85M | 233.99M | 257.56M | 190.78M | 240.86M | 274.48M | 231.10M | 244.70M | 352.19M | 554.11M | 340.84M | 233.74M | 217.06M | 147.71M | 125.43M | 70.91M | 54.70M | 123.12M | 125.76M | 107.31M | 105.81M | 71.48M | 90.41M | 129.70M | 169.80M | 138.50M | 128.30M | 58.80M |
| Operating Income Ratio | 2.45% | 4.98% | 8.68% | 9.98% | 7.88% | 8.99% | 12.04% | 10.47% | 10.89% | 13.71% | 17.44% | 15.71% | 13.40% | 14.12% | 11.10% | 10.05% | 6.13% | 4.90% | 10.43% | 11.05% | 10.88% | 10.98% | 8.07% | 10.28% | 14.50% | 18.59% | 15.55% | 18.91% | 16.40% |
| Total Other Income/Expenses | -21.69M | -21.88M | -1.53M | -1.33M | -12.25M | -21.19M | -8.92M | -18.27M | -32.74M | -53.68M | 2.83M | 4.40M | -6.97M | -9.45M | -6.59M | -24.78M | -2.44M | -2.03M | -4.17M | -3.62M | 432.00K | -2.89M | 8.38M | 5.99M | -1.30M | -3.10M | -6.00M | -2.90M | 500.00K |
| Income Before Tax | 26.58M | 88.97M | 232.46M | 256.23M | 255.17M | 219.67M | 265.57M | 212.84M | 211.96M | 298.51M | 556.94M | 345.24M | 226.77M | 207.61M | 141.12M | 100.65M | 68.48M | 52.68M | 118.95M | 122.14M | 107.74M | 102.93M | 79.86M | 96.41M | 128.40M | 166.70M | 149.30M | 131.20M | 59.30M |
| Income Before Tax Ratio | 1.35% | 4.00% | 8.62% | 9.92% | 10.54% | 8.20% | 11.65% | 9.64% | 9.43% | 11.62% | 17.53% | 15.91% | 13.00% | 13.51% | 10.60% | 8.07% | 5.92% | 4.72% | 10.07% | 10.73% | 10.92% | 10.68% | 9.02% | 10.96% | 14.36% | 18.25% | 16.77% | 19.33% | 16.54% |
| Income Tax Expense | 17.98M | -15.81M | 85.19M | 64.88M | 81.62M | 97.78M | 136.13M | 69.75M | 78.91M | 109.33M | 192.05M | 123.60M | 73.44M | 71.56M | 51.28M | 35.31M | 24.61M | 19.86M | 44.92M | 44.47M | 39.86M | 38.08M | 29.55M | 34.71M | 41.70M | 62.80M | 55.70M | 49.50M | 19.10M |
| Net Income | 8.60M | 104.78M | 147.27M | 191.36M | 173.55M | 121.89M | 129.44M | 143.09M | 133.05M | 189.18M | 364.89M | 221.65M | 153.33M | 136.05M | 89.85M | 65.35M | 43.87M | 32.82M | 74.03M | 77.67M | 67.88M | 64.84M | 50.31M | 61.70M | 86.70M | 103.90M | 93.60M | 81.70M | 40.20M |
| Net Income Ratio | 0.44% | 4.71% | 5.46% | 7.41% | 7.17% | 4.55% | 5.68% | 6.48% | 5.92% | 7.36% | 11.49% | 10.22% | 8.79% | 8.85% | 6.75% | 5.24% | 3.79% | 2.94% | 6.27% | 6.83% | 6.88% | 6.73% | 5.68% | 7.01% | 9.70% | 11.37% | 10.51% | 12.04% | 11.21% |
| EPS | 0.17 | 2.10 | 2.93 | 3.66 | 3.13 | 2.21 | 2.45 | 2.58 | 2.29 | 3.20 | 6.23 | 3.66 | 2.47 | 2.18 | 1.42 | 1.03 | 0.68 | 0.47 | 1.06 | 1.10 | 0.86 | 0.79 | 0.60 | 0.72 | 1.00 | 1.22 | 1.42 | 1.07 | 0.51 |
| EPS Diluted | 0.17 | 2.07 | 2.86 | 3.63 | 3.10 | 2.16 | 2.36 | 2.55 | 2.25 | 3.11 | 5.94 | 3.52 | 2.38 | 2.11 | 1.40 | 1.02 | 0.67 | 0.47 | 1.04 | 1.07 | 0.85 | 0.78 | 0.60 | 0.72 | 0.99 | 1.19 | 1.36 | 1.02 | 0.50 |
| Weighted Avg Shares Out | 49.71M | 50.00M | 50.19M | 52.30M | 55.52M | 55.17M | 52.81M | 55.41M | 58.00M | 59.07M | 58.61M | 60.60M | 62.07M | 62.37M | 63.33M | 63.51M | 64.78M | 69.42M | 70.05M | 70.73M | 78.64M | 81.73M | 83.47M | 85.40M | 87.08M | 84.89M | 83.33M | 79.16M | 78.82M |
| Weighted Avg Shares Out (Dil) | 49.86M | 50.53M | 51.43M | 52.77M | 55.93M | 56.48M | 54.85M | 56.10M | 59.06M | 60.89M | 61.45M | 63.03M | 64.55M | 64.55M | 64.30M | 64.13M | 65.58M | 70.51M | 71.36M | 72.63M | 79.54M | 83.13M | 83.92M | 85.64M | 87.89M | 87.02M | 87.31M | 83.04M | 80.40M |
Nu Skin (NUS) Q4 Earnings Top Estimates, Revenues Decline Y/Y
Nu Skin's (NUS) fourth-quarter 2023 results reflect the persistence of macroeconomic challenges and hurdles related to business transformation, offset by growth in some regions.
Nu Skin Enterprises (NUS) Surpasses Q4 Earnings and Revenue Estimates
Nu Skin Enterprises (NUS) came out with quarterly earnings of $0.37 per share, beating the Zacks Consensus Estimate of $0.29 per share. This compares to earnings of $0.89 per share a year ago.
Nu Skin Enterprises, Inc. (NUS) Q4 2023 Earnings Call Transcript
Nu Skin Enterprises, Inc. (NUS) Q4 2023 Earnings Call Transcript
Nu Skin Enterprises Reports Fourth Quarter and Full-year 2023 Results Above Company Guidance
PROVO, Utah--(BUSINESS WIRE)--Nu Skin Enterprises Inc. (NYSE: NUS) today announced fourth quarter and full-year 2023 results slightly above its latest guidance. Executive Summary Q4 2023 vs. Prior-year Quarter Revenue $488.6 million; (6)% (1)% FX impact or $(7.2) million Rhyz revenue...
Things to Consider Ahead of Nu Skin's (NUS) Q4 Earnings
Nu Skin's (NUS) fourth-quarter 2023 earnings will likely reflect the adverse impact of macroeconomic challenges like a slowdown in consumer spending. Unfavorable currency translations pose concerns.
Analysts Estimate Nu Skin Enterprises (NUS) to Report a Decline in Earnings: What to Look Out for
Nu Skin (NUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Stocks You Have Never Heard of Pay Massive Dividends
We decided to screen our 24/7 Wall St. dividend research database for companies that pay gigantic dividends that investors have likely never heard of.
Dividend Danger Zone: 3 High-Yield Stocks That Could Follow in Walgreens' Footsteps
Investing in high-yield dividend stocks is one of the best ways to accumulate wealth to fund your retirement. For the better part of a century, dividend-paying companies have far outperformed non-payers with less risk.
Product Launches Aid Nu Skin (NUS), Macroeconomic Hurdles Ail
Nu Skin (NUS) is benefiting from the Nu Vision 2025 strategy driven by a dynamic affiliate opportunity platform. However, escalating macroeconomic pressures are hampering key markets.
Nu Skin Enterprises to Discuss Company Strategy and Opportunities at ICR Conference
PROVO, Utah--(BUSINESS WIRE)--Nu Skin execs are scheduled to present at ICR Conference. The company also shared Q4 preliminary revenue with full results to be reported Feb. 14.
Source: https://incomestatements.info
Category: Stock Reports